SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

Начало・Списък с акции・Ipsen SA.

Ipsen SA.

Затворен

СекторФинансови

165.6 0.67

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

164.5

Максимум

166.2

Ключови измерители
By Trading Economics
Приходи	-225M 110M
Продажби	36M 1.9B
P/E Средно за сектора	30.921 57.736
Дивидентна доходност	0.84
Марж на печалбата	5.899
Служители	5,535
EBITDA	-171M 466M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-12.83% downside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.84% 4.52%
Следващи печалби	30.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.2B 14B
Предишно отваряне	164.93
Предишно затваряне	165.6

Настроения в новините

By Acuity

45%

55%

160 / 439 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

99.85 / 104 Подкрепа & съпротива

Ipsen SA. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14.05.2026 г., 22:27 ч. UTC

Придобивния, сливания и поглъщания

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14.05.2026 г., 22:12 ч. UTC

Печалби

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14.05.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs

15.05.2026 г., 00:00 ч. UTC

Печалби

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14.05.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14.05.2026 г., 23:56 ч. UTC

Пазарно говорене

Gold Prices Rise on Strong Demand -- Market Talk

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14.05.2026 г., 23:28 ч. UTC

Пазарно говорене

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's One Nation Party Leads In The Polls -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.05.2026 г., 22:35 ч. UTC

Пазарно говорене

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14.05.2026 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

LVMH Agrees to Sell Marc Jacobs -- WSJ

14.05.2026 г., 22:06 ч. UTC

Пазарно говорене

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14.05.2026 г., 22:00 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q EPS 18c >NU

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q Rev $4.97B >NU

Сравнение с други в отрасъла

Ценова промяна

Ipsen SA. Прогноза

Ценова цел

By TipRanks

-12.83% надолу

12-месечна прогноза

Среден 144 EUR -12.83%

Висок 170 EUR

Нисък 130 EUR

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Ipsen SA. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Ipsen SA. през последните 3 месеца.

Техническа оценка

By Trading Central

99.85 / 104Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

160 / 439 Класиране в Финансови

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.